Advanced Search

Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2009 December;51(4) > Panminerva Medica 2009 December;51(4):205-13

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEPANMINERVA MEDICA

A Journal on Internal Medicine

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6

Frequency: Quarterly

ISSN 0031-0808

Online ISSN 1827-1898

 

Panminerva Medica 2009 December;51(4):205-13

THE STATE OF LIVER TRANSPLANTATION 

Metabolic Syndrome and liver transplantation

Kadayifci A.

Division of Gastroenterology, Department of Medicine, University of Gaziantep, Gaziantep, Turkey

Metabolic Syndrome comprises a cluster of risk factors that predispose to mainly cardiovascular disease and its complications. It is also closely associated with liver steatosis and fibrosis. Metabolic Syndrome and its hepatic manifestation, non-alcoholic fatty liver disease, are very prevalent both in general population and also pre- and post-transplantation setting. Important life-style changes and immunosuppressive treatment after liver transplantation seem to have significant effects for the development of the Metabolic Syndrome: increased risks for liver transplant recipients and challenges for successful treatment outcomes. Its association with major vascular events and negative effects on progression of fibrosis in recurrent hepatitis C after transplantation have been major concerns for transplant patients in recent years. There is no standard therapeutic approach to these patients, and well-designed prospective studies are certainly needed to define management strategy. Until such specific data become available, early aggressive risk factor modification should be aimed and each component of the syndrome should be cared separately.

language: English


FULL TEXT  REPRINTS

top of page